Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Sheppard, Karen E; Cullinane, C; Hannan, Katherine; Wall, Meaghan; Chan, Joanna; Barber, Francis; Foo, Jung; Cameron, Donald; Neilsen, Amelia; Ng, Pui Y.; Ellul, Jason; Kleinschmidt, Margarete; Kinross, Kathryn M.; Bowtell, David D.; Christensen, James G.; Hicks, Rodney J.; Johnstone, Ricky; McArthur, Grant; Hannan, Ross; Phillips, Wayne A.; Pearson, Richard B
Background: Ovarian cancer is the major cause of death from gynaecological malignancy with a 5 year survival of only ∼30% due to resistance to platinum and paclitaxel-based first line therapy. Dysregulation of the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) and RAS/extracellular signal-regulated kinase (ERK) pathways is common in ovarian cancer, providing potential new targets for 2nd line therapy. Methods:We determined the inhibition of proliferation of an extensive...[Show more]
|Collections||ANU Research Publications|
|Source:||European Journal of Cancer|
|01_Sheppard_Synergistic_inhibition_of_2013.pdf||1.26 MB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.